Brainsway Ltd. current report, Q3 FY2024

Brainsway Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by Brainsway Ltd., a foreign private issuer, on August 29, 2024. The report covers the month of August 2024 and serves to disclose a material corporate event rather than financial results.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement but a disclosure of a personnel appointment.

Material Changes

The primary material change disclosed is the appointment of Richard A. Bermudes, M.D., as the Company's Chief Medical Officer. This information is detailed in Exhibit 99.1 attached to the filing.

Guidance, Outlook, and Risks

The filing text does not provide specific guidance, outlook, management commentary on financial performance, or new risk factors. The document incorporates by reference into the Company's Registration Statement on Form S-8 (filed April 22, 2019) and Form F-3 (filed July 22, 2024).

Key Facts for Investor Verification

  • Richard A. Bermudes, M.D., has been appointed as Chief Medical Officer.
  • The appointment was announced on August 29, 2024.
  • Further details regarding Dr. Bermudes' background and role are contained in Exhibit 99.1.
  • No financial data or operational metrics are included in this specific filing.